Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
P 1 (3)
P 3 (1)

Trial Status

Recruiting2
Unknown1
Active Not Recruiting1
Not Yet Recruiting1
Terminated1

Clinical Trials (6)

Showing 6 of 6 trials
NCT04620603Phase 1Active Not Recruiting

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

NCT04865939Phase 3RecruitingPrimary

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NCT06630247Phase 1Terminated

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05874921Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05494411UnknownPrimary

Named Patient Program for Mitomycin for Pyelocalyceal Solution

NCT05979909Phase 1Not Yet Recruiting

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Showing all 6 trials

Research Network

Activity Timeline